Safety of Megestrol Acetate in Palliating Anorexia-Cachexia Syndrome in Patients with Castration-Resistant Prostate Cancer.
10.3346/jkms.2013.28.5.687
- Author:
Sungwoo HONG
1
;
In Gab JEONG
;
Dalsan YOU
;
Jae Lyun LEE
;
Jun Hyuk HONG
;
Hanjong AHN
;
Choung Soo KIM
Author Information
1. Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. cskim@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Cachexia;
Castration-Resistant Prostate Cancer;
Docetaxel;
Megestrol Acetate;
Survival
- MeSH:
Aged;
Aged, 80 and over;
Anorexia/complications/*drug therapy;
Antineoplastic Agents/therapeutic use;
Antineoplastic Agents, Hormonal/*therapeutic use;
Cachexia/complications/*drug therapy;
Castration;
Humans;
Kaplan-Meier Estimate;
Male;
Megestrol Acetate/*therapeutic use;
Middle Aged;
Proportional Hazards Models;
Prostatic Neoplasms/complications/*drug therapy/mortality;
Taxoids/therapeutic use
- From:Journal of Korean Medical Science
2013;28(5):687-692
- CountryRepublic of Korea
- Language:English
-
Abstract:
There are concerns whether megestrol acetate (MA) stimulates the growth of prostate cancer in castration-resistant prostate cancer (CRPC). We evaluated the effect of cumulative doses of MA on the disease-specific survival (DSS) in patients with CRPC who were receiving Docetaxel-based chemotherapy. From July 2003 through June 2009, we identified 109 consecutive patients with CRPC and who had received docetaxel-based chemotherapy. Of these patients, 68 (62.4%) have not received MA, whereas 21 patients (19.3%) and 20 patients (18.3%) had received low dose MA (total < or = 18,400 mg) and high dose MA (total > 18,400 mg), respectively. We assessed the effect of several variables on DSS. None of the clinicopathological variables differed among the three groups. When comparing DSS using Kaplan-Meier analysis, there was no statistically significant survival differences among the three groups (P = 0.546). Using multivariate Cox proportional analyses with backward elimination, the number of docetaxel cycles was only significant factor predicting DSS (HR: 0.578, 95% CI: 0.318-0.923, P = 0.016). Cumulative doses of MA as adjuvant treatment for patients with CRPC and who are receiving docetaxel-based chemotherapy, did not affect their DSS. Therefore, MA can be safely administered in cachexic patients with CRPC.
